AAAAAA

   
Results: 1-8 |
Results: 8
Tissue factor as a therapeutic target
Authors: Key, NS Bach, RR
Citation: Ns. Key et Rr. Bach, Tissue factor as a therapeutic target, THROMB HAEM, 85(3), 2001, pp. 375-376
Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation
Authors: Ozcan, M Morton, CT Solovey, A Dandelet, L Bach, RR Hebbel, RP Slungaard, A Key, NS
Citation: M. Ozcan et al., Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation, THROMB HAEM, 85(2), 2001, pp. 250-255
Patient/caregiver assessment of convenience in the use of recombinant activated factor VII (rVIIa; NovoSeven (R)) in home therapy
Authors: Page, MJ Key, NS Rockwood, T
Citation: Mj. Page et al., Patient/caregiver assessment of convenience in the use of recombinant activated factor VII (rVIIa; NovoSeven (R)) in home therapy, BL COAG FIB, 11, 2000, pp. S51-S52
Sensitization of CD4(+) T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects
Authors: Reding, MT Wu, HY Krampf, M Okita, DK Diethelm-Okita, BM Christie, BA Key, NS Conti-Fine, BM
Citation: Mt. Reding et al., Sensitization of CD4(+) T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects, THROMB HAEM, 84(4), 2000, pp. 643-652
Induction of tissue factor procoagulant activity in myelomonocytic cells inoculated by the agent of human granulocytic ehrlichiosis
Authors: Behl, R Klein, MB Dandelet, L Bach, RR Goodman, JL Key, NS
Citation: R. Behl et al., Induction of tissue factor procoagulant activity in myelomonocytic cells inoculated by the agent of human granulocytic ehrlichiosis, THROMB HAEM, 83(1), 2000, pp. 114-118
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk
Authors: Thorland, EC Drost, JB Lusher, JM Warrier, I Shapiro, A Koerper, MA Dimichele, D Westman, J Key, NS Sommer, SS
Citation: Ec. Thorland et al., Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk, HAEMOPHILIA, 5(2), 1999, pp. 101-105
CD4(+) T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects
Authors: Reding, MT Wu, H Krampf, M Okita, DK Diethelm-Okita, BM Key, NS Conti-Fine, BM
Citation: Mt. Reding et al., CD4(+) T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects, THROMB HAEM, 82(2), 1999, pp. 509-515
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
Authors: Key, NS Aledort, LM Beardsley, D Cooper, HA Davignon, G Ewenstein, BM Gilchrist, GS Gill, JC Glader, B Hoots, WK Kisker, CT Lusher, JM Rosenfield, CG Shapiro, AD Smith, H Taft, E
Citation: Ns. Key et al., Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors, THROMB HAEM, 80(6), 1998, pp. 912-918
Risultati: 1-8 |